Study Comparing Ripretinib and Sunitinib for Advanced GIST After Imatinib Treatment

Inclusion Criteria

• Must be 18 years or older.
• Have a confirmed diagnosis of GIST and provide a tumor sample.
• Must have a report confirming the genetic makeup of the tumor. If not available, a new sample may be needed.
• Must have not responded to or cannot tolerate imatinib.
• Be in relatively good health with an ECOG score of 0 to 2.
• Women of childbearing age must have a negative pregnancy test before starting the study.
• Must agree to use effective birth control during the study.
• Must have at least one tumor that can be measured by scans.
• Have good organ function and blood cell counts.
• Any side effects from previous treatments must be mild or resolved.
• Must understand the study and agree to participate by signing a consent form.
• Cannot participate in other clinical trials while in this study, except for observational studies.

Exclusion Criteria

• Have received other treatments for advanced GIST besides imatinib.
• Have another cancer that could affect the study results.
• Have active cancer spread to the brain.
• Have serious heart conditions or recent heart attack.
• Have a heart pumping ability below 50%.
• Have had recent blood clots or bleeding issues.
• Have a prolonged QT interval on an ECG.
• Have had major surgery recently.
• Have significant other health issues.
• Have active infections like HIV or hepatitis.
• Are pregnant or breastfeeding.
• Have allergies to the study drugs.
• Have digestive issues that prevent taking oral medication.